Spyre Therapeutics, Inc. SYRE Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s cash ratio?
- Spyre Therapeutics, Inc. (SYRE) reported cash ratio of 1.1× in Q1 2026.
- How has Spyre Therapeutics, Inc.'s cash ratio changed year-over-year?
- Spyre Therapeutics, Inc.'s cash ratio increased by 66.3% year-over-year, from 0.7× to 1.1×.
- What is the long-term trend for Spyre Therapeutics, Inc.'s cash ratio?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s cash ratio has grown at a -23.2% compound annual growth rate (CAGR), from 5.5× to 1.5×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.